Olivier Chapet1, Corina Udrescu2, Ronan Tanguy3, Alain Ruffion4, Pascal Fenoglietto5, Marie-Pierre Sotton6, Marian Devonec4, Marc Colombel7, Patrice Jalade6, David Azria5. 1. Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France. Electronic address: olivier.chapet@chu-lyon.fr. 2. Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France; Department of Medical Physics, Centre Hospitalier Lyon Sud, Pierre Benite, France. 3. Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France. 4. Department of Urology, Centre Hospitalier Lyon Sud, Pierre Benite, France. 5. Department of Radiation Oncology, Centre Val d'Aurelle, Montpellier, France. 6. Department of Medical Physics, Centre Hospitalier Lyon Sud, Pierre Benite, France. 7. Department of Urology, Hopital Edouard Herriot, Lyon, France.
Abstract
PURPOSE: This study assessed the contribution of ahyaluronic acid (HA) injection between the rectum and the prostate to reducing the dose to the rectal wall in stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: As part of a phase 2 study of hypofractionated radiation therapy (62 Gy in 20 fractions), the patients received a transperineal injection of 10 cc HA between the rectum and the prostate. A dosimetric computed tomographic (CT) scan was systematically performed before (CT1) and after (CT2) the injection. Two 9-beam intensity modulated radiation therapy-SBRT plans were optimized for the first 10 patients on both CTs according to 2 dosage levels: 5 × 6.5 Gy (PlanA) and 5 × 8.5 Gy (PlanB). Rectal wall parameters were compared with a dose-volume histogram, and the prostate-rectum separation was measured at 7 levels of the prostate on the center line of the organ. RESULTS: For both plans, the average volume of the rectal wall receiving the 90% isodose line (V90%) was reduced up to 90% after injection. There was no significant difference (P=.32) between doses received by the rectal wall on CT1 and CT2 at the base of the prostate. This variation became significant from the median plane to the apex of the prostate (P=.002). No significant differences were found between PlanA without HA and PlanB with HA for each level of the prostate (P=.77, at the isocenter of the prostate). CONCLUSIONS: HA injection significantly reduced the dose to the rectal wall and allowed a dose escalation from 6.5 Gy to 8.5 Gy without increasing the dose to the rectum. A phase 2 study is under way in our department to assess the rate of acute and late rectal toxicities when SBRT (5 × 8.5 Gy) is combined with an injection of HA.
PURPOSE: This study assessed the contribution of ahyaluronic acid (HA) injection between the rectum and the prostate to reducing the dose to the rectal wall in stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: As part of a phase 2 study of hypofractionated radiation therapy (62 Gy in 20 fractions), the patients received a transperineal injection of 10 cc HA between the rectum and the prostate. A dosimetric computed tomographic (CT) scan was systematically performed before (CT1) and after (CT2) the injection. Two 9-beam intensity modulated radiation therapy-SBRT plans were optimized for the first 10 patients on both CTs according to 2 dosage levels: 5 × 6.5 Gy (PlanA) and 5 × 8.5 Gy (PlanB). Rectal wall parameters were compared with a dose-volume histogram, and the prostate-rectum separation was measured at 7 levels of the prostate on the center line of the organ. RESULTS: For both plans, the average volume of the rectal wall receiving the 90% isodose line (V90%) was reduced up to 90% after injection. There was no significant difference (P=.32) between doses received by the rectal wall on CT1 and CT2 at the base of the prostate. This variation became significant from the median plane to the apex of the prostate (P=.002). No significant differences were found between PlanA without HA and PlanB with HA for each level of the prostate (P=.77, at the isocenter of the prostate). CONCLUSIONS:HA injection significantly reduced the dose to the rectal wall and allowed a dose escalation from 6.5 Gy to 8.5 Gy without increasing the dose to the rectum. A phase 2 study is under way in our department to assess the rate of acute and late rectal toxicities when SBRT (5 × 8.5 Gy) is combined with an injection of HA.
Authors: Nicholas G Zaorsky; Timothy N Showalter; Gary A Ezzell; Paul L Nguyen; Dean G Assimos; Anthony V D'Amico; Alexander R Gottschalk; Gary S Gustafson; Sameer R Keole; Stanley L Liauw; Shane Lloyd; Patrick W McLaughlin; Benjamin Movsas; Bradley R Prestidge; Al V Taira; Neha Vapiwala; Brian J Davis Journal: Adv Radiat Oncol Date: 2016-10-20
Authors: Angèle Dubouloz; Michel Rouzaud; Lev Tsvang; Wilko Verbakel; Mikko Björkqvist; Nadine Linthout; Joana Lencart; Juan María Pérez-Moreno; Zeynep Ozen; Lluís Escude; Thomas Zilli; Raymond Miralbell Journal: Radiat Oncol Date: 2018-06-19 Impact factor: 3.481
Authors: David Pasquier; Emilie Bogart; François Bonodeau; Thomas Lacornerie; Eric Lartigau; Igor Latorzeff Journal: BMC Cancer Date: 2018-05-16 Impact factor: 4.430